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Abstract
Alzheimer’s and Parkinson’s diseases are neurodegenerative diseases where several 
biomarkers have suggested that a single measurement is not a sufficient biomarker. The 
observation of increased concentration of cadmium (Cd), lead (Pb), and silver (Ag) in 
erythrocytes by inductively coupled plasma mass spectrometry (ICP-MS) shows a need 
to look for new approaches to understand the complex synchronistic effects of the cell 
metabolism. We have used a simplified scheme to follow some of the effects by following 
a hierarchy of reactions simplified to monitor elements in peripheral blood cells, e.g., 
erythrocytes. Erythrocytes carry oxygen to cells and carbon dioxide and waste to the 
lungs and back when passing from different organs including the brain. Erythrocytes 
also have the capacity to carry metal ions, which may be transferred to other organs, e.g., 
brain, despite the blood-brain barrier (BBB) and choroid plexus filter. If transfer of Cd, 
Pb, and Ag is continued too long, the repair systems may not be sufficient, and epigenetic 
effects on DNA and RNA may begin. Peripheral blood cells, e.g., erythrocytes, may help 
get earlier individual indications of changes at the cell level by using ICP-MS.
Keywords: hierarchy, cells, Cd, Pb, Ag, erythrocytes, Alzheimer’s disease, Parkinson’s 
disease, epigenetic changes, element profile, ICP-MS
1. Introduction
The cell metabolism is a complex balance of proteins, fatty acids, carbohydrates, metal ions, 
and trace elements regulated by DNA and RNA in nucleus. The metabolism of proteins is 
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further influenced by a noncoding RNA, e.g., siRNA, which involves molecular reactions and 
metal ions. Reactions involving metal ions and molecules may create difficulties in interpret-
ing which components are involved due to similar symptoms that may be created by different 
reactions at the cellular level, masking symptoms. A simplified summary of reactions is given 
in Figure 1.
In Figure 1, it is suggested that cell reactions proceed in a hierarchical manner, along with 
three main pathways [1]. The first pathway involves metal ions associated with ligands with 
different strengths due to properties of metal ions, binding compounds, pH, redox state, and 
medium where this reaction takes place. The second pathway involves organic compounds 
with nucleophilic or electrophilic properties resulting in products favoring the most reactive 
partner. The third pathway involves radical reactions which may be fast or slow depending 
on cell demand. The brain has high needs for oxygen and uses about 20% of the total oxygen. 
Oxygen is important for many reactions but can produce H2O2 or OH*− radicals that can cause severe damage when not under control. The reaction pathway used for processing a 
component will be dependent on DNA, RNA, and cell demand.
According to the Food and Drug Administration (FDA) [2], as many as 70% of drugs for 
Alzheimer’s disease, 75% cancer diseases, 50% arthritis diseases, and 40% asthma diseases are 
Figure 1. The flow of compounds and metal ions between cells is dependent on the three main chemical pathways in a 
hierarchy. The first path involves free radical-induced production of compounds where hydroxyl radical and solvated 
electron reactions may be involved. The second path involves electrophilic and nucleophilic compounds forming 
products adequate to the cells. The third path involves metal ions and ligands dependent on the previous two pathways 
but adapted to cell demand. The symbolic schedule indicates that compounds and metal ions may reach DNA and 
RNA not controlled by evolutionary developed genome adapted to cell demand. Small changes of DNA and RNA may 
take place, an epigenetic change, which may be restored or adapted, but large damages will present symptoms and are 
difficult to restore.
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not effective. The report may indicate compliance problems and difficulties with translating 
symptoms from reactions, but above all there is a need of more sensitive and selective systems 
to handle diseases.
Personalized medicine may be one way to improve systems by better diagnostic tools, design-
ing drugs, etc. Peripheral blood has been used in medical diagnosis for a very long time, 
because, among other things, it is easily accessible. In the search for signs of lack or excess 
of minerals and trace elements in the disease, the interest has been focused mainly on blood, 
plasma, or serum. The utilization of blood cells as a marker model is proposed here. The ele-
ment profile of blood cells may be one part to improve the present systems.
It is a challenge to separate normal reactions of cell metabolism from early pathophysiological 
differences. The identification of early changes in cells is important for correct diagnosis and 
optimal treatment when symptoms indicate the beginning of a disease. Blood cells which 
pass through several organs may be useful as they exchange information between systems 
involved. One example is the erythrocytes which transport oxygen from the lungs to differ-
ent recipients and waste products back, e.g., CO2 and hemoglobin, for decomposition and excretion. Besides the important transport of oxygen to oxygen-dependent organs, e.g., the 
brain, liver, and kidneys, they carry metal ions. When cells are growing old or have accumu-
lated metal ions, the metabolism capacity of oxygen or transfer process of metal ions may be 
changed. By following the variations in the metal concentrations of the erythrocytes, sum-
marized in an element profile, multifactorial diseases may be identified earlier. Observations 
of increased concentrations of metal ions, e.g., lead (Pb), (cadmium) Cd, and (silver) Ag, in the 
erythrocytes of patients with Alzheimer’s and Parkinson’s diseases by inductively coupled 
plasma mass spectrometry (ICP-MS) indicate possibilities to observe early steps in the patho-
physiological processes and early epigenetic changes [3–5].
An early indication of changed metal ion homeostasis by an element profile is the change of 
important cell reactions. The element profile may be looked upon as the integrated results 
of reactions of metal ions and ligands. Cells with different life span, e.g., erythrocytes and 
platelets, help in the interpretation of possible changes. Changes in the element profile may 
give early biochemical, physiological, and pathophysiological information of changed cell 
metabolism and indicate defects in vulnerable organs.
2. Comparison of significant increased concentrations of Pb, Cd, and 
Ag in the erythrocytes of patients with Alzheimer’s and Parkinson’s 
diseases
Patients with Alzheimer’s disease were selected in Finland [3] and patients with Parkinson’s 
disease in Sweden [4, 5]. The mean concentrations of Pb in patients with Alzheimer’ disease 
[3] and Parkinson’s disease were 157 μg/kg (wet weight) and 67.8 μg/kg, respectively, about 
two times higher than that of Parkinson’s disease [5]. The concentration of Cd in erythrocytes 
of patients with Alzheimer’s disease was 11.5 μg/kg (wet weight) and 1.9 μg/kg in Parkinson’s 
disease, about five times higher in Alzheimer’s disease. An increased concentration of Ag was 
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observed in both Alzheimer’s and Parkinson’s diseases 7.4 μg/kg (wet weight) and 2.8 μg/kg, 
respectively, about two times higher in Alzheimer’s disease. Pb, Cd, and Ag maintain the 
hierarchical effects on weaker associated metal ions in relation to association constants 
and not to DNA control when the balance of metal ions or binding compounds cannot be 
 controlled [1]. It is important to identify early changes to understand the pathophysiological 
mechanisms and find proper treatments. Some effects will be discussed in relation to the 
imbalance of metal ion homeostasis and significant concentration changes of Pb, Cd, and Ag 
in the erythrocytes.
3. Reduced filter capacity of the kidneys and control of adrenal 
glands may promote the uptake of Pb, Cd, and Ag in erythrocytes
The reasons for the significant increased concentration of Pb, Cd, and Ag in erythrocytes of 
patients with Alzheimer’s and Parkinson’s diseases are not well understood. The absorption 
of essential elements starts in the small intestine, e.g., duodenum, less in the jejunum, and 
ileum, and large intestine. It is a complex interplay between intestinal bacteria and the liver, 
kidneys, pancreas, and bone. It is probable that Pb, Cd, and Ag may use the same carrier 
systems as essential elements in the blood. After the uptake of Pb, Cd, and Ag, they are trans-
ported to other organs for use or storage in the bone and also balanced by the kidneys and 
adrenal glands. The absorbed Pb, Cd, and Ag may not be properly controlled by the kidneys 
and adrenal glands. Excretion of Cd is very low and thus Cd is accumulated. The half-life 
of Cd in humans is about 20–35 years [6]. Most of the Cd is deposited in the kidneys, liver, 
pancreas, and lungs. Excess Pb is also accumulated often in the bone with a half-life of about 
5–19 years [7]. The half-life of Ag in humans is not well documented, but an indicative value 
may be about 50 days [8]. Erythrocytes have a half-life of about 120 days. The accumulated 
silver in the erythrocytes may indicate a leakage of silver from root tips with silver amal-
gam [1, 9]. The contribution of Ag from food, drinking water, and vaccines is probably low. 
An imbalance of metal ion homeostasis in cell membrane carrier systems may interfere with 
essential element metabolism in favor of an epigenetic change. The decreased filter capac-
ity of the kidneys and decreased control by parathyroid and adrenal glands can to some 
extent explain the accumulation of elements in the erythrocytes and the transport to other 
organs, e.g., brain. If imbalance of metal ion homeostasis in the erythrocytes is lasting too 
long, DNA control may decrease. The kidneys and adrenal glands in collaboration with the 
hypothalamus, pineal gland, pituitary glands, and choroid plexus are known to involve in 
the control of electrolyte and water balance [10, 11]. Chronic exposure to low concentrations 
of compounds with Pb, Cd, and Ag and loss of binding compounds, e.g., decreased available 
selenium and compounds with low metal binding capacity, may decrease the filter selectivity 
and disrupt DNA control. The background of decreased filter capacity is of course complex, 
but a part of the problem may be found in nutrition, e.g., lack of adequate selenium, phytate 
(inositol hexakisphosphate), flavonoids, and tannins balancing metal ion flux. In addition, 
environmental exposure, lack of exercise, smoking habit, and genetic factors may contribute. 
The decreased filter capacity of the kidneys and decreased brain control may promote the 
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transport of metal ions and compounds not controlled by DNA, thus opening for epigenetic 
changes. Besides the transport of Pb, Cd, and Ag by erythrocytes in the blood, carriers like 
albumin, metallothionein, transferrin, and ceruloplasmin carry metal ions to recipients in the 
body. It is possible that the kidneys provide Pb, Cd, and Ag to erythrocytes, thus disturbing 
other carrier systems of elements, e.g., Na, K, Mg, Ca, and Se. It is not known if the imbal-
ance of metal ion homeostasis in erythrocytes of patients with Alzheimer’s and Parkinson’s 
diseases starts in the kidneys and adrenal glands or how the imbalance of metal ions in the 
erythrocytes is transferred to other organs. The transport of Pb, Cd, and Ag from the mem-
branes and further selection of metal ions are provided by different systems, e.g., transient 
receptor protein (TRP) channels [12–14], solute carrier (SLC) protein families [15, 16], and 
ATP binding cassette (ABC) families [17, 18] and calmodulin families [19, 20]. Interestingly, 
difference in binding capacity of the membranes gives an additional way to regulate metal ion 
flow controlled by DNA.
4. Increased concentration of Pb, Cd, and Ag in the erythrocytes and 
effects of messengers and cellular overload in metal ion homeostasis 
with reference to calcium homeostasis
The discussion will be limited to some effects of elements, which involve the important mes-
sengers in Alzheimer’s and Parkinson’s diseases: calcium, selenium, and inosine 1,4,5-tri-
phosphate (IP3), the latter being an example of an organic messenger [21]. Calcium is an 
important intracellular messenger involved in the release of, e.g., [Ca2+], from the rough and 
smooth endoplasmic reticulum (ER), ryanodine receptor, TRP, mitochondria, and calmodulin 
family, and apoptosis. Alterations in [Ca2+] homeostasis have been suggested in neurological 
diseases, such as Parkinson’s and Alzheimer’s diseases [22–24]. The metabolism and flux of 
calcium in the ER are suggested to be dependent on, e.g., selenoprotein N, selenoprotein 
S, and selenoprotein T, critical for maintaining [Ca2+] [25–27]. Microglia were implicated in 
Alzheimer’s disease [28]. If Pb, Cd, and Ag enter in the microglia local defense systems, they 
may be decreased. Sodium and potassium ions are important for nerve signals and in glu-
cose metabolism [29]. O’Brien and Legge [30] showed that erythrocytes may be mapped by 
using potassium ions with μ-PIXE technique resulting in a disclike structure indicating high 
concentration of potassium in the erythrocytes. Erythrocytes and neuron cells carry insulin 
receptors [31, 32]. Insulin facilitates the introduction of sodium-potassium pumps, indicating 
that insulin and insulin receptors also support the distribution of Na and K in membranes 
[33]. As Li, Na, and K often have lower affinity to receptors and carriers than Pb, Cd, and Ag, 
interactions can be expected in the uptake and transport of channels. In many cells, transport 
of K can be made in Ca channels, e.g., Gardos channels [34, 35], by SLC family [36]. Insulin 
facilitates the introduction of sodium-potassium pumps indicating that insulin and insulin 
receptors also support the distribution of these elements in neuron cells. Cd may interact with 
Na and K-ATPase, indicating a possible interaction with Na and K ions [37]. Ca and Mg in 
cells often are carried by members of calmodulin families [38]. Similar size of ionic radius of 
cadmium 0.97 A and Ca 0.99 A may explain competition of binding sites. Cd in calmodulin 
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molecule causes conformational changes of calmodulin [39]. The binding constants for Pb 
and Cd in calmodulin are higher than those of Mg and Ca. When cells are not controlled by 
DNA, Pb, Cd, and Ag may change the metabolism of Mg and Ca. It is not known if and how 
Pb, Cd, and Ag of erythrocytes compete with carrier systems of patients with Alzheimer’s 
and Parkinson’s diseases. In Alzheimer’s disease acetylcholine receptors involve Ca [21, 40] 
which may be repressed by Pb, Cd, and Ag. In cells the calcium concentration is low and 
kept under strong control because correct concentration of Ca is important for the regula-
tion of ATP synthesis in mitochondria and organelle functions. Uncontrolled release of Ca in 
cells disturbs ATP synthesis and apoptosis regulation. Cellular overload of Pb, Cd, and Ag is 
interesting in view of possible interactions of cell metabolism in three ways: (1) competition of 
Pb, Cd, and Ag with weaker associated metal ions as K, Mg, and Ca; (2) interaction of Pb, Cd, 
and Ag with selenium compounds in mitochondria and ER; and (3) reaction with phosphate 
groups in ATP and IP3. Reactive selenium compounds may be identified in different parts of 
ER important in the regulation of Ca [25]. Studies on harmful effects of metal ions often refer 
to one element at a time; very little is known about the effects of accumulated Pb, Cd, and Ag 
and their synchronistic damage. Dementia in Alzheimer’s and Parkinson’s diseases has been 
demonstrated in several studies [41]. The effects of Pb and Cd were demonstrated in mentally 
retarded children [42]. Pb, Cd, and Ag may also “hitchhike” endogenous carriers of essential 
metal ions making the interpretation of metal ion homeostasis not controlled by DNA reac-
tions more complex. It is likely that Pb, Cd, and Ag may be able to repress Mg and Ca in cell 
DNA and disrupt DNA and RNA control due to synchronistic damaging effects.
5. Possible effects of Pb, Cd, and Ag on blood-brain barrier (BBB) 
filter and choroid plexus in relation to metal ion imbalance and 
selenium homeostasis
In Alzheimer’s and Parkinson’s diseases, malfunctions may be attributed to damage in differ-
ent regions. The transport of compounds and metal ions to the brain is controlled by blood-
brain barrier and by CSF in the choroid plexus [43–45]. The blood-brain barrier is constructed 
of endothelial cells, astrocyte end-feet, and pericytes forming diffuse barriers, tight junctions, 
receptors, and channels for carrier-mediated transport [46]. Leukocytes and larger molecules 
cannot pass into the BBB as well as in other vessels, but, e.g., oxygen, carbon dioxide, iron, 
glucose, and certain amino acids can pass. If Pb, Cd, and Ag from erythrocytes enter the 
BBB, an imbalance may be expected of metal ions and compounds in regions of, e.g., the 
hippocampus, hypothalamus, pituitary gland, pineal gland, and cortex. Part of Pb, Cd, and 
Ag in the erythrocytes may “hitchhike” tight junctions, channels, and carriers for essential 
elements in BBB and enter neuron cells, astrocytes, and microglia in a way not controlled by 
DNA. Pericytes and endothelial cells have mitochondria and ER which need selenium for 
proper function of, e.g., Ca and Mg. Mitochondria synthesize ATP, and lowered selenium 
and Mg may decrease the production of ATP and complicate synthesis systems in ER for the 
control of Ca and Mg. Activated neutrophil granulocytes can produce (H2O2) damage in tight junctions and receptors in membranes of pericytes and endothelial cells when there are local 
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low selenium status and low activity of protecting GSH-Px (GPx1 and GPx4). The ER stores 
selenium [25] and metal ions for maintaining calcium metabolism. Imbalance in metal ion 
homeostasis and selenium homeostasis can hamper DNA control of metal flux to different 
organelles, e.g., ER, mitochondria, Golgi, and nuclei. Besides erythrocyte transport of Pb, Cd, 
and Ag, albumin may carry Pb, Cd, and Ag which can react with tight junctions and receptors 
on pericytes and pass, loaded with Pb, Cd, and Ag producing reactive oxygen species (ROS). 
Pb, Cd, and Ag can interact with elements in mitochondria, e.g., Mg, Ca, Mn, and Se, and 
disturb ER storage of calcium and action of selenophosphate synthetase. The introduction 
of selenium in amino acids and UGA (stop codon) is very important for cell metabolism. 
Albumin may carry heme groups having an antioxidant effect, which decreases the risk of 
ROS production [47]. Microglia can attack receptors and tight junctions on pericytes around 
the endothelial cells producing ROS damage and perhaps open for albumin entrance carrying 
Pb, Cd, and Ag. The brain is composed of 80% water and uses aquaporin, AQ1, AQ4, and 
AQ9, for water balance [10]. Apart from water control, Pb, Cd, and Ag can use aquaporin for 
passage [11]. If Pb and Cd can pass into the mitochondria, Mn may be displaced and trigger 
SOD to produce ROS. Pb, Ca, and Ag may use the SLC system [48], “hitchhike,” and transfer 
elements through the BBB in a way not controlled by DNA. Choroid plexus epithelial cells 
are rich in selenium [25] and may act as an additional barrier against metal ions and toxic 
compounds [43]. If erythrocytes are overloaded with Cd, Pb, and Ag, some ions may pass the 
BBB in other regions of the brain, e.g., hippocampus and cortex, and produce local imbalance 
of metal ions and selenium homeostasis in the brain.
6. Effects of Pb, Cd, and Ag on insulin receptors in brain cells and 
energy homeostasis
Increased concentrations of Pb, Cd, and Ag do not only affect the transfer of metal ions but 
also may influence the metabolism of proteins and peptides [49–51]. In plasma about 30% of 
Ca and about 40% Zn may be carried by albumin, but albumin also carries other elements and 
organic compounds [47, 52–54]. In the study of albumin, Pb and Cd decreased the transport of 
taxifolin [55]. Albumin in the blood carries 1–10% of glucose. If Pb, Cd, and Ag bind to albumin, 
transport of organic compounds, e.g., glucose, may be decreased. Many peptides and proteins 
in the BBB are transported by carrier in membranes, e.g., SLC and ABC families, which can be 
blocked by Pb, Cd, and Ag. T4 (thyroxin) in the blood is transported by transthyretin to the 
BBB [56]. T4 is dependent on selenium deiodinases for transfer to active T3 (thyronine) [57]. 
As both deiodinases and T4 and T3 have reactive selenium and iodine groups can Pb, Cd, 
and Ag disturb selenium homeostasis. Insulin present in the brain is not known to be directly 
involved in glucose metabolism but may assist in the regulation of energy homeostasis [49, 50]. 
The brain has many insulin receptors, which is highest in the hippocampus. The association 
of metal ions to insulin receptors in neuron cells may be similar as that of erythrocytes when 
Cd, Pb, and Ag interact with K+ and Na+ ions with insulin receptors [32]. Insulin binding 
sites to insulin receptor may be occupied by Pb, Cd, and Ag and decrease transport. Memory 
problems connected to the hippocampus may be explained to some extent by a decreased 
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transport of insulin, availability of glucose, and the antioxidant capacity of the brain involved 
in energy homeostasis [49, 50]. If the concentration of Pb, Cd, and Ag of the erythrocytes is 
too high, insulin transport in the brain may be decreased with less capacity to control energy 
homeostasis and hormone balance of insulin, leptin, and serotonin [49].
7. Axonal transport and possible interactions of Pb, Cd, and Ag
The axonal transport of mitochondria [58, 59] may be blocked by Pb, Cd, and Ag. Mitochondria 
were transported by kinesin, dynein, and myosin motors. Accumulation of Pb, Cd, and Ag in 
the erythrocytes may interact with transport in neurons due to carry-over effects.
In the synapse dopamine and acetylcholine are transported in the vesicles. The observed 
accumulation of Pb, Cd, and Ag in the erythrocytes may present two problems: (1) lowered 
dopamine production and (2) blocking acetylcholine.
Dopamine synthesis may be disturbed by Cd, Pb, and Ag in the medulla of adrenal glands, 
neuron cells, and substantia nigra. Transport of molecules, e.g., dopamine, may be blocked by 
Pb, Cd, and Ag. Interactions with aldosterone formed in cortex (adrenal glands) are known 
as an important regulator of Na, K may be disturbed. The high concentration of Cd, Pb, and 
Ag may interact with the hormone controlled by, e.g., hypothalamus, thalamus, and adrenal 
glands.
8. Changed metal ion and selenium homeostasis by overloaded 
Pb, Cd, and Ag in erythrocytes related to receptor functions in 
Alzheimer’s and Parkinson’s diseases
Important calcium-dependent receptors were reported in Section 3. Receptors may respond 
to metal ions and compounds but in a hierarchy to respond correctly. Receptors in the dif-
ferent brain regions may need to be restored; excess Pb, Cd, and Ag may block restoring 
procedures. Receptor feasibility is dependent on metal ions and organic compounds to main-
tain hierarchy in selectivity and efficacy. If receptors are exposed to overload of Pb, Cd, and 
Ag in erythrocytes, receptor activity may be destroyed or renewal not be possible. Patients 
with Alzheimer’s and Parkinson’s diseases with changed metal ion homeostasis meet incom-
plete selenium proteins or not properly adapted proteins [60, 61]. In Parkinson’s disease, 
dopamine synthesis in neuron cells, e.g., substantia nigra and hypothalamus, is decreased. 
In parkinsonian patient’s postmortem substantia nigra, increased concentration of iron was 
observed [62]. Transport of iron by SLC41 (membrane iron carrier) to the substantia nigra 
can be disrupted by erythrocytes overloaded with Pb, Cd, and Ag and decrease the synthesis 
of dopamine. Lowered Ca homeostasis is coupled with selenium deficiency in ER in both 
Parkinson’s and Alzheimer’s diseases [26, 63–69]. In Alzheimer’s disease increased produc-
tion of β-amyloid is implicated. Patients with Alzheimer’s and Parkinson’s diseases may have 
in common increased Pb, Cd, and Ag in the erythrocytes with possible interactions with 
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selenoproteins and phosphate groups in nuclei, ER, mitochondrial ATP, and IP3 [27]. SelP 
(selenoprotein P) in the brain with about 10 Se atoms is important to support different brain 
regions with selenium. As SelP is very reactive, Pb, Cd, and Ag and their protective role may 
be blocked [70]. A more basic work is necessary to understand how the regulation of metal ion 
homeostasis in cells is related to selenium homeostasis at the local level.
9. Epigenetic effects on DNA and RNA repair systems after exposure 
to Cd, Pb, and Ag from erythrocytes
Cells exposed to Cd, Pb, and Ag can disturb the genomic stability which is dependent on Mg 
[71, 72]. DNA is dependent on efficient repair systems due to as many as 10,000 errors/cell/day 
[73]. If Cd, Pb, and Ag from erythrocytes are introduced to cells, repair systems will not work 
properly [74]. Deformed molecules or decreased production of important protective com-
pounds may initiate problems in cell metabolism, e.g., it starts wrong apoptosis signals and Cd, 
Pb, and Ag may compete with repair systems, e.g., enzymes and ligases of DNA polymerases 
[75, 76]. Excess Cd, Pb, and Ag can also impair Zn-dependent RNA polymerases by competing 
with the active center in the binding domain and also create cross-linking of DNA [77–79].
10. Conclusions
ICP-MS may be used for the determination of the element profile of erythrocytes as a bio-
marker in Alzheimer’s and Parkinson’s diseases. The increased concentration of Pb, Cd, and 
Ag in erythrocytes in Alzheimer’s and Parkinson’s diseases indicates changes in the filter 
capacity of the kidneys combined with the changes of the adrenal glands. Studying multifac-
torial problems using element profiles in diseases may help to identify early changes in the 
pathophysiological process and epigenetic progress. The increase of Pb, Cd, and Ag in the 
erythrocytes may indicate changes in metal ion homeostasis at the cellular level in other parts 
of the body, e.g., the brain.
Parkinson’s and Alzheimer’s diseases are neurodegenerative diseases. A variety of treatment 
recommendations in the treatment guidelines have been proposed, including physical activ-
ity and disease-modifying medication, which should be initiated at the early stage of the 
disease. The complex synchronistic effects at the cellular level when Cd, Pb, and Ag enter in 
a noncontrolled way may be approached by using ICP-MS. It is hoped that this knowledge 
will allow the identification of novel therapeutic targets that will eventually lead to a more 
efficient treatment, based on the patient’s individual genetic predispositions.
Many candidate biomarkers of the neurodegenerative diseases have been proposed in the 
scientific literature, but in all cases, their variability in cross-sectional studies is considerable, 
and therefore no single measurement has proven to serve a useful marker, possibly lacking 
the power of directly predicting disease risk, as the underlying physiological change may per 
se be harmless and without functional compromise.
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This necessitates the development of new effective strategies for the prevention and early 
diagnosis of such conditions. Contrary to the common perception that personalized medicine 
is completely based on a genetic approach, clinical subtypes, personality, lifestyle, aging, and 
comorbidities constitute the true personalized medicine.
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